1. Home
  2. TMQ vs LXRX Comparison

TMQ vs LXRX Comparison

Compare TMQ & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trilogy Metals Inc.

TMQ

Trilogy Metals Inc.

HOLD

Current Price

$3.74

Market Cap

705.7M

ML Signal

HOLD

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$2.02

Market Cap

703.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMQ
LXRX
Founded
2004
1995
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
705.7M
703.3M
IPO Year
2012
2000

Fundamental Metrics

Financial Performance
Metric
TMQ
LXRX
Price
$3.74
$2.02
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.15
AVG Volume (30 Days)
2.4M
2.0M
Earning Date
04-02-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.78
EPS
N/A
N/A
Revenue
N/A
$49,803,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
60.24
52 Week Low
$1.30
$0.71
52 Week High
$11.29
$2.53

Technical Indicators

Market Signals
Indicator
TMQ
LXRX
Relative Strength Index (RSI) 41.63 53.28
Support Level $3.35 $1.50
Resistance Level $4.53 $2.53
Average True Range (ATR) 0.28 0.12
MACD -0.04 -0.00
Stochastic Oscillator 13.64 55.84

Price Performance

Historical Comparison
TMQ
LXRX

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: